Abstract
Little information is available on the prevalence of drug-resistance mutations in patients harboring the human immunodeficiency virus type 1 (HIV-1) circulating recombinant form (CRF)07_BC variant in Sichuan, China. This study examined 375 plasma samples from patients with HIV-1 who were infected with the CRF07_BC strain, including 104 drug-naive participants and 271 in whom antiretroviral therapy (ART) had failed. Only one participant in the drug-naive group had a drug-resistance mutation (M46L), compared with 31.73% of those in whom ART had failed. Further analysis showed that 19.56% of strains contained mutations conferring resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs) alone, 0.74% were resistant to nucleoside reverse transcriptase inhibitors (NRTIs) alone, and 11.44% were dual-resistant to both NRTIs and NNRTIs. The most common mutation in the ART-failure group was M184V (35.88%), K103N (45.01%), Y181C (17.33%), and G190S/A (15.88%). The percentages of HIV-1 strains resistant to lamivudine, emtricitabine, efavirenz, etravirine, and nevirapine were 10.70%, 10.70%, 28.04%, 7.75%, and 26.20%, respectively. To explore site variants possibly related to drug resistance, variations in the ancestor/consensus CRF07_BC sequences from the therapy-naive and ART-failure groups were compared, and seven mutations at six positions were identified as being significantly differently distributed between the two groups (p<0.05). Detailed sequence data will provide information on CRF07_BC genetic characterizations, and improve our understanding of antiretroviral susceptibility and the evolution of drug-resistance mutations. This will be valuable in developing and implementing local public-health approaches for HIV drug-resistance prevention and treatment.
Keywords: HIV-1, CRF07_BC, drug resistance, Sichuan, China
References
- Ariyoshi K, Matsuda M, Miura H, Tateishi S, Yamada K, Sugiura W. Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection. J Acquir Immune Defic Syndr. 2003;33:336–342. doi: 10.1097/00126334-200307010-00007. [DOI] [PubMed] [Google Scholar]
- Li H, Geng Q, Guo W, Zhuang D, Li L, Liu Y, Bao Z, Liu S, Li J. Screening for and verification of novel mutations associated with drug resistance in the HIV type 1 subtype B(’) in China. PLoS One. 2012;7:e47119. doi: 10.1371/journal.pone.0047119. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Li X P, Xing H, Wang Z, Si X F, Wang L E, Cheng H, Cui W G, Jiang S L, Liao L J, Zhou H W, Huang J H, Peng H, Ma P F, Shao Y M. Study of HIV-1 drug resistance in patients receiving free antiretroviral therapy in China. Virol Sin. 2007;22:233–240. doi: 10.1007/s12250-007-0027-y. [DOI] [Google Scholar]
- Li Z, Huang Y, Ouyang Y, Xing H, Liao L, Jiang S, Shao Y, Ma L. Mutation covariation of HIV-1 CRF07_BC reverse transcriptase during antiretroviral therapy. J Antimicrob Chemother. 2013;68:2521–2524. doi: 10.1093/jac/dkt228. [DOI] [PubMed] [Google Scholar]
- Liao L, Xing H, Li X, Ruan Y, Zhang Y, Qin G, Shao Y. Genotypic analysis of the protease and reverse transcriptase of HIV type 1 isolates from recently infected injecting drug users in western China. AIDS Res Hum Retroviruses. 2007;23:1062–1065. doi: 10.1089/aid.2007.0050. [DOI] [PubMed] [Google Scholar]
- Pereira C F, Paridaen J T. Anti-HIV drug development—an overview. Curr Pharm Des. 2004;10:4005–4037. doi: 10.2174/1381612043382459. [DOI] [PubMed] [Google Scholar]
- Reuman E C, Rhee S Y, Holmes S P, Shafer R W. Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations. J Antimicrob Chemother. 2010;65:1477–1485. doi: 10.1093/jac/dkq140. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Richman D D, Morton S C, Wrin T, Hellmann N, Berry S, Shapiro M F, Bozzette S A. The prevalence of antiretroviral drug resistance in the United States. AIDS. 2004;18:1393–1401. doi: 10.1097/01.aids.0000131310.52526.c7. [DOI] [PubMed] [Google Scholar]
- Tee K K, Pybus O G, Li X J, Han X, Shang H, Kamarulzaman A, Takebe Y. Temporal and spatial dynamics of human immunodeficiency virus type 1 circulating recombinant forms 08_BC and 07_BC in Asia. J Virol. 2008;82:9206–9215. doi: 10.1128/JVI.00399-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wu H, Zhang H J, Zhang X M, Xu H F, Wang M, Huang J D, Zheng B J. Identification of drug resistant mutations in HIV-1 CRF07_BC variants selected by nevirapine in vitro. PLoS One. 2012;7:e44333. doi: 10.1371/journal.pone.0044333. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Xiao L, Wu Z, Luo W, Wei X. Quality of life of outpatients in methadone maintenance treatment clinics. J Acquir Immune Defic Syndr. 2010;53Suppl1:S116–120. doi: 10.1097/QAI.0b013e3181c7dfb5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Yu G, Li Y, Li J, Diao L, Yan X, Lin P, He Q, Wang Y, Fu X, Yang F, Long Q. Genetic diversity and drug resistance of HIV type 1 circulating recombinant Form_BC among drug users in Guangdong Province. AIDS Res Hum Retroviruses. 2009;25:869–875. doi: 10.1089/aid.2008.0312. [DOI] [PubMed] [Google Scholar]
- Yuan D F L, Xi J. Moleculo-epidemiological study of HIV-1/AIDS among 77 men having sex with men in Sichuan province. Chinese J STD/AIDS Prev Cont. 2011;17:410–413. [Google Scholar]
- Zeng P L Y. HIV-1 genotypic diversity and prevalence of drug resistance among treatment naive HIV-infected individuals in Chengdu of China. Virus Genes. 2013;47:6. doi: 10.1007/s11262-013-0958-3. [DOI] [PubMed] [Google Scholar]